Technical Analysis for SMMT - Summit Therapeutics plc

Grade Last Price % Change Price Change
grade D 1.55 1.97% 0.03
SMMT closed up 1.97 percent on Friday, January 17, 2020, on 2.01 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical SMMT trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.97%
Crossed Above 20 DMA Bullish 1.97%
MACD Bullish Signal Line Cross Bullish 1.97%
BB Squeeze Ended Range Expansion 1.97%
Up 3 Days in a Row Strength 1.97%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.
Medicine Medical Specialties Diseases Drug Discovery Dementia Muscular Dystrophy Duchenne Muscular Dystrophy Clostridioides Difficile Clostridium Difficile Infection

Is SMMT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.46
52 Week Low 1.1324
Average Volume 30,250
200-Day Moving Average 1.53
50-Day Moving Average 1.53
20-Day Moving Average 1.49
10-Day Moving Average 1.48
Average True Range 0.07
ADX 10.24
+DI 25.07
-DI 16.44
Chandelier Exit (Long, 3 ATRs ) 1.39
Chandelier Exit (Short, 3 ATRs ) 1.63
Upper Bollinger Band 1.58
Lower Bollinger Band 1.40
Percent B (%b) 0.84
BandWidth 12.19
MACD Line -0.01
MACD Signal Line -0.02
MACD Histogram 0.0077
Fundamentals Value
Market Cap 19.2 Million
Num Shares 12.4 Million
EPS -0.36
Price-to-Earnings (P/E) Ratio -4.31
Price-to-Sales 4.01
Price-to-Book 26.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.64
Resistance 3 (R3) 1.64 1.60 1.63
Resistance 2 (R2) 1.60 1.58 1.61 1.62
Resistance 1 (R1) 1.58 1.57 1.59 1.58 1.61
Pivot Point 1.54 1.54 1.55 1.55 1.54
Support 1 (S1) 1.52 1.52 1.53 1.52 1.49
Support 2 (S2) 1.48 1.51 1.49 1.48
Support 3 (S3) 1.46 1.48 1.48
Support 4 (S4) 1.46